

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	Moya Caffrey et al.	Art Unit :	1621
Serial No. :	10/546,131	Examiner :	Shailendra Kumar
Filed :	August 19, 2005	Conf. No. :	9916
Title :	ADAMANTANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM		

MAIL STOP RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. Copies of International Search Reports for WO 01/94338, WO 03/041707, WO 03/080579, WO 04/073704, WO 04/105798, WO 04/105797, WO 04/105796, WO 05/014529 and WO 05/025571 are also enclosed.

Applicants provide a listing below of commonly owned co-pending U.S. patent applications that are included on the PTO-1449. Please note that the commonly owned co-pending U.S. patent applications were filed as U.S. national phase patent applications under 35 U.S.C. §371, and therefore the listing includes a reference to the PCT publication number for each of commonly owned co-pending U.S. patent applications.

The PTO-1449 lists the commonly owned co-pending U.S. patent applications by their corresponding published PCT publication number. The published U.S. patent applications are listed on the PTO-1449 under both the U.S. publication numbers and the PCT publication numbers.

U.S. Patent Application Serial No./  
Published U.S. Patent Application

6,949,539  
7,129,246  
US-2005-0090524-A1  
US 2006-0247257 A1  
10/558,354  
10/558,342  
10/558,322  
10/567,711  
10/572,276

Corresponding Published PCT  
Patent Application

WO 01/94338  
WO 03/041707  
WO 03/080579  
WO 04/073704  
WO 04/105798  
WO 04/105797  
WO 04/105796  
WO 05/014529  
WO 05/025571

This filing is being made with the filing of a Request for Continued Examination. No fee is required.

Respectfully submitted,

Date: December 19, 2006

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21515110.doc

Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-466US1	Application No. 10/546,131
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Moya Caffrey et al.	
		Filing Date August 19, 2005	Group Art Unit 1621
(37 CFR §1.98(b))			

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3,464,998	09/02/1969	Krimmel			
	AB	3,471,491	10/07/1969	Venkatachala et al.			
	AC	4,349,552	09/14/1982	Takaya et al.			
	AD	4,751,292	06/14/1988	Fox			
	AE	US 2004/0236109	11/25/2004	Van Straten et al.			
	AF	US 2005/0090524	04/28/2005	Ford et al.			
	AG	6,949,539	09/27/2005	Alcaraz et al.			
	AH	7,129,246	10/31/2006	Alcaraz et al.			
	AI	US 2006/0247257	11/02/2006	Dixon			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AJ	BE 650919 A	07/23/1964	Belgium			English Abstract only	
	AK	DE 1943404 A	12/17/1970	Germany			English Abstract only	
	AL	EP 0002065	05/30/1979	Europe				
	AM	EP 0867436	09/30/1998	Europe			English Abstract only	
	AN	WO 95/04720	02/16/1995	WIPO				
	AO	WO 99/29660	06/17/1999	WIPO				
	AP	WO 99/29661	06/17/1999	WIPO				
	AQ	WO 99/18074	04/15/1999	WIPO				
	AR	WO 00/61569	10/19/2000	WIPO				
	AS	WO 01/42194	06/14/2001	WIPO				
	AT	WO 01/44170	06/21/2001	WIPO				
	AU	WO 02/096426	12/05/2002	WIPO				
	AV	WO 03/042191	05/22/2003	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>06275-466US1</b>	Application No. <b>10/546,131</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Moya Caffrey et al.</b>	
		Filing Date <b>August 19, 2005</b>	Group Art Unit <b>1621</b>
(37 CFR §1.98(b))			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AW	WO 03/080579	10/02/2003	WIPO				
	AX	WO 04/073704	09/02/2004	WIPO				
	AY	WO 04/105798	12/09/2004	WIPO				
	AZ	WO 04/105797	12/09/2004	WIPO				
	AAA	WO 04/105796	12/09/2004	WIPO				
	ABB	WO 05/014529	02/17/2005	WIPO				
	ACC	WO 05/025571	03/24/2005	WIPO				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	ADD	Accession No. 2003:42109, CAS Registry No. 487064-48-2
	AEE	Alcaraz et al., "Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155
	AFF	Alcaraz et al., "Novel P2X7 Receptor Antagonists" <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4043-4046 (2003)
	AGG	Baxter et al., "Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4047-4050 (2003)
	AHH	Bourrie et al., "SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties," <i>Eur. J. of Pharm.</i> , 456:123-131 (2002)
	ALL	Costakis et al., "Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles", <i>Journal of Medicinal Chemistry</i> 14(12):1222-1223 (1971)
	AJJ	Dell'Antonio et al., "Antinociceptive effect of a new P2X7 antagonist, oxidized ATP, in arthritic rats", <i>Neuroscience Letters</i> 327:87-90 (2002)
	AKK	Di Virgilio et al., "Purinergic P2X <sub>7</sub> -Receptor: A Pivotal Role in Inflammation and Immunomodulation", <i>Drug Development Research</i> 45:207-213 (1998)
	ALL	Ferrari et al., "Extracellular ATP Triggers IL-1 $\beta$ Release by Activating the Purinergic P2Z Receptor of Human Macrophages", <i>J. Immunol.</i> 159:1451-1458 (1997)
	AMM	Ferrari et al., "Purinergic Modulation of Interleukin-1 $\beta$ Release from Microglial Cells Stimulated with Bacterial Endotoxin", <i>J. Exp. Med.</i> 185(3):579-582 (1997)
	ANN	Henderson et al., "Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist", <i>Cytokine</i> 3(3):246-249 (1991)
	AOO	Ho et al., "Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[ <i>g</i> ] quinoline as a VLA-4 Antagonist", <i>J. Org. Chem.</i> 65:6743-6748, page 6745, scheme 5, (27) (2000)
	APP	Humphreys et al., "Modulation of P2X <sub>7</sub> nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes", <i>Journal of Leukocyte Biology</i> 64:265-273 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-466US1	Application No. 10/546,131
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Moya Caffrey et al.	
		Filing Date August 19, 2005	Group Art Unit 1621

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Design ID	Document
	AQQ	Kadota et al., "Significance of IL-1 $\beta$ and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)", <i>Clin. Exp. Immunol.</i> 103:461-466 (1996)
	ARR	Khurana et al., "Clinical aspects of rheumatoid arthritis", <i>Pathophysiology</i> , Volume 12, Issue 3, Abstract (2005)
	ASS	Kirkham, "Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis", <i>Annals of the Rheumatic Diseases</i> , 50:395-400 (1991)
	ATT	Li et al., "Should atherosclerosis be considered a cancer of the vascular wall?" <i>Medical Hypotheses</i> , 64:694-698 (2005)
	AUU	Otterness et al., "Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions", <i>Agent Act 39 (Suppl):109-120</i> (1993)
	AVV	Mackenzie et al., "Could rheumatoid arthritis have an infectious aetiology?" <i>Drug Discovery Today: Disease Mechanism</i> , Volume 2, Issue 3, Abstract (2005)
	AWW	Rains et al., "Sulfasalazine, A review of its Pharmacological Properties and Therapeutic Efficacy in the Treatment of Rheumatoid Arthritis", <i>Drugs</i> 50:137-156 (1995)
	AXX	Richards et al., "Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy," <i>Eur. J. of Medic. Chem.</i> , 41:950-969 (2006)
	AYY	Sakito et al., "Interleukin 1 $\beta$ , Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy", <i>Respiration</i> 63:42-48 (1996)
	AZZ	Seventh International Symposium on Adenosine & Adenine Nucleotides: "Adenosin-und Purinrezeptoren als Targets neuer Arzneimittel", <i>Deutsche Apotheker Zeitung</i> 142(36):62-65 (2002)
	AAAA	STN International, File REGISTRY, see RN 405068-97-5, 405070-41-9, 405076-22-4, 14 April 2002
	ABBB	STN International, File REGISTRY, see RN 445032-09-7, 30 August 2002
	ACCC	STN International, File CHEMCATS, Accession no. 2001:48444, 14 May 2001, NS18552, 2-Quinolincarboxamide, N-(tricyclo[3.3.1.1.3,7]dec-1-ylmethyl), CAS Registry No. 313688-07-2
	ADDD	STN International, File REGISTRY, see RN 401622-10-4, 24 March 2002
	AEEE	van den Berg. "Lessons from animal models of osteoarthritis, <i>Curr. Opin. Rheumatol.</i> 13(5): 452-6 (2001)
	AFFF	Yu et al., "Inhibition of IL-1 Release from Human Monocytes and Suppression of Streptococcal Cell Wall and Adjuvant-induced Arthritis in Rats by an Extract of <i>Tripterygium wilfordii</i> Hook", <i>Gen. Pharmac.</i> 25(6):1115-1122 (1994)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	